Era of Streptococcus pneumoniae

ABSTRACT

The invention provides era polypeptides and DNA (RNA) encoding era polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing era polypeptides to screen for antibacterial compounds.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional PatentApplication No. 60/031,879 filed Nov. 27, 1996; U.S. Provisional PatentApplication No. 60/017,670 filed May 14, 1996; This application is ac-i-p of U.S. patent application Ser. No. 08/919,573 filed Jul. 10,1997; U.S. patent application Ser. No. 08/858,207, filed May 14, 1997,and International Application Number PCT/US97/08272 filed May 14, 1997.

FIELD OF THE INVENTION

This invention relates to newly identified polynucleotides andpolypeptides, and their production and uses, as well as their variants,agonists and antagonists, and their uses. In particular, in these and inother regards, the invention relates to novel polynucleotides andpolypeptides of the Era-type GTPases family, hereinafter referred to as"Era".

BACKGROUND OF THE INVENTION

The Streptococci make up a medically important genera of microbes knownto cause several types of disease in humans, including, for example,otitis media, conjunctivitis, pneumonia, bacteremia, meningitis,sinusitis, pleural empyema and endocarditis, and most particularlymeningitis, such as for example infection of cerebrospinal fluid. Sinceits isolation more than 100 years ago, Streptococcus pneumoniae has beenone of the more intensively studied microbes. For example, much of ourearly understanding that DNA is, in fact, the genetic material waspredicated on the work of Griffith and of Avery, Macleod and McCartyusing this microbe. Despite the vast amount of research withStreptococcus pneumoniae, many questions concerning the virulence ofthis microbe remain. It is particularly preferred to employStreptococcal genes and gene products as targets for the development ofantibiotics.

The frequency of Streptococcus pneumoniae infections has risendramatically in the past 20 years. This has been attributed to theemergence of multiply antibiotic resistant strains and an increasingpopulation of people with weakened immune systems. It is no longeruncommon to isolate Streptococcus pneumoniae strains which are resistantto some or all of the standard antibiotics. This has created a demandfor both new anti-microbial agents and diagnostic tests for thisorganism.

The Era gene in Escherichia coli codes for an essential protein. Theprotein, Era is a GTPase and is able to autophosphorylate itself at aserine and/or threonine residue (March P E., 1992. Membrane-associatedGTPases in bacteria. Molecular Microbiology 6: 1253-1257). It is foundin both soluble and membrane compartments of E. coli cells and has beenfound to be localized to the membrane at points consistent with a rolein septation or nucleoid segregation (Gollop, N. & March P. E., 1991.Localization of the membrane binding sites of Era in Escherichia coli.Research in Microbiology 142: 301-307). Homologous proteins have beenfound in a variety of bacteria and show functional complementation(Pillutla, R. C., Sharer, J. D., Gulati, P. S., Wu, E., Yamashita, Y.,Lerner, C. G., Inouye, M., & March, P. E., 1995. Cross-speciescomplementation of the indispensable Escherichia coli Era genehighlights amino acid regions essential for activity. Journal ofBacteriology 177:2194-2196).

Clearly, there is a need for factors, such as the novel compounds of theinvention, that have a present benefit of being useful to screencompounds for antibiotic activity. Such factors are also useful todetermine their role in pathogenesis of infection, dysfunction anddisease. There is also a need for identification and characterization ofsuch factors and their antagonists and agonists which can play a role inpreventing, ameliorating or correcting infections, dysfunctions ordiseases.

The polypeptides of the invention have amino acid sequence homology to aknown Streptococcus mutans spg protein (SWISS-PROT: locus ERA₋₋ STRMU,accession P37214).

SUMMARY OF THE INVENTION

It is an object of the invention to provide polypeptides that have beenidentified as novel Era polypeptides by homology between the amino acidsequence set out in Table 1 [SEQ ID NO: 2] and a known amino acidsequence or sequences of other proteins such as Streptococcus mutans spgprotein.

It is a further object of the invention to provide polynucleotides thatencode Era polypeptides, particularly polynucleotides that encode thepolypeptide herein designated Era.

In a particularly preferred embodiment of the invention, thepolynucleotide comprises a region encoding Era polypeptides comprisingthe sequence set out in Table 1 [SEQ ID NO:1] which includes a fulllength gene, or a variant thereof.

In another particularly preferred embodiment of the invention, there isa novel Era protein from Streptococcus pneumoniae comprising the aminoacid sequence of Table 1 [SEQ ID NO:2], or a variant thereof.

In accordance with another aspect of the invention, there is provided anisolated nucleic acid molecule encoding a mature polypeptide expressibleby the Streptococcus pneumoniae 0100993 strain contained in thedeposited strain.

As a further aspect of the invention, there are provided isolatednucleic acid molecules encoding Era, particularly Streptococcuspneumoniae Era, including mRNAs, cDNAs, genomic DNAs. Furtherembodiments of the invention include biologically, diagnostically,prophylactically, clinically or therapeutically useful variants thereof,and compositions comprising the same.

In accordance with another aspect of the invention, there is providedthe use of a polynucleotide of the invention for therapeutic orprophylactic purposes, in particular genetic immunization. Among theparticularly preferred embodiments of the invention are naturallyoccurring allelic variants of Era and polypeptides encoded thereby.

As another aspect of the invention, there are provided novelpolypeptides of Streptococcus pneumoniae referred to herein as Era aswell as biologically, diagnostically, prophylactically, clinically ortherapeutically useful variants thereof, and compositions comprising thesame.

Among the particularly preferred embodiments of the invention arevariants of Era polypeptide encoded by naturally occurring alleles ofthe era gene.

In a preferred embodiment of the invention, there are provided methodsfor producing the aforementioned Era polypeptides.

In accordance with yet another aspect of the invention, there areprovided inhibitors to such polypeptides, useful as antibacterialagents, including, for example, antibodies.

In accordance with certain preferred embodiments of the invention, thereare provided products, compositions and methods for assessing Eraexpression, treating disease, for example, otitis media, conjunctivitis,pneumonia, bacteremia, meningitis, sinusitis, pleural empyema andendocarditis, and most particularly meningitis, such as for exampleinfection of cerebrospinal fluid, assaying genetic variation, andadministering a Era polypeptide or polynucleotide to an organism toraise an immunological response against a bacteria, especially aStreptococcus pneumoniae bacteria.

In accordance with certain preferred embodiments of this and otheraspects of the invention, there are provided polynucleotides thathybridize to Era polynucleotide sequences, particularly under stringentconditions.

In certain preferred embodiments of the invention, there are providedantibodies against era polypeptides.

In other embodiments of the invention, there are provided methods foridentifying compounds which bind to or otherwise interact with andinhibit or activate an activity of a polypeptide or polynucleotide ofthe invention comprising: contacting a polypeptide or polynucleotide ofthe invention with a compound to be screened under conditions to permitbinding to or other interaction between the compound and the polypeptideor polynucleotide to assess the binding to or other interaction with thecompound, such binding or interaction being associated with a secondcomponent capable of providing a detectable signal in response to thebinding or interaction of the polypeptide or polynucleotide with thecompound; and determining whether the compound binds to or otherwiseinteracts with and activates or inhibits an activity of the polypeptideor polynucleotide by detecting the presence or absence of a signalgenerated from the binding or interaction of the compound with thepolypeptide or polynucleotide.

In accordance with yet another aspect of the invention, there areprovided Era agonists and antagonists, preferably bacteriostatic orbactericidal agonists and antagonists.

In a further aspect of the invention, there are provided compositionscomprising a Era polynucleotide or a Era polypeptide for administrationto a cell or to a multicellular organism.

Various changes and modifications within the spirit and scope of thedisclosed invention will become readily apparent to those skilled in theart from reading the following descriptions and from reading the otherparts of the present disclosure.

GLOSSARY

The following definitions are provided to facilitate understanding ofcertain terms used frequently herein.

"Host cell" is a cell which has been transformed or transfected, or iscapable of transformation or transfection by an exogenous polynucleotidesequence.

"Identity," as known in the art, is a relationship between two or morepolypeptide sequences or two or more polynucleotide sequences, asdetermined by comparing the sequences. In the art, "identity" also meansthe degree of sequence relatedness between polypeptide or polynucleotidesequences, as the case may be, as determined by the match betweenstrings of such sequences. "Identity" and "similarity" can be readilycalculated by known methods, including but not limited to thosedescribed in (Computational Molecular Biology, Lesk, A. M., ed., OxfordUniversity Press, New York, 1988; Biocomputing: Informatics and GenomeProjects, Smith, D. W., ed., Academic Press, New York, 1993; ComputerAnalysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G.,eds., Humana Press, New Jersey, 1994; Sequence Analysis in MolecularBiology, von Heinje, G., Academic Press, 1987; and Sequence AnalysisPrimer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York,1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073(1988). Preferred methods to determine identity are designed to give thelargest match between the sequences tested. Methods to determineidentity and similarity are codified in publicly available computerprograms. Preferred computer program methods to determine identity andsimilarity between two sequences include, but are not limited to, theGCG program package (Devereux, J., et al., Nucleic Acids Research 12(1):387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S. F. et al., J. Molec.Biol. 215: 403-410 (1990). The BLAST X program is publicly availablefrom NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBINLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990). As an illustration, by a polynucleotide having anucleotide sequence having at least, for example, 95% "identity" to areference nucleotide sequence of SEQ ID NO: 1 it is intended that thenucleotide sequence of the polynucleotide is identical to the referencesequence except that the polynucleotide sequence may include up to fivepoint mutations per each 100 nucleotides of the reference nucleotidesequence of SEQ ID NO: 1. In other words, to obtain a polynucleotidehaving a nucleotide sequence at least 95% identical to a referencenucleotide sequence, up to 5% of the nucleotides in the referencesequence may be deleted or substituted with another nucleotide, or anumber of nucleotides up to 5% of the total nucleotides in the referencesequence may be inserted into the reference sequence. These mutations ofthe reference sequence may occur at the 5' or 3' terminal positions ofthe reference nucleotide sequence or anywhere between those terminalpositions, interspersed either individually among nucleotides in thereference sequence or in one or more contiguous groups within thereference sequence. This example correlates to the following algebraicexpression, namely (1-N_(n) /X_(n))×100, wherein N_(n) is the number ofnucleotides in the first polynucleotide that are substituted, deleted orinserted when compared to the reference polynucleotide, which is X_(n)nucleotides in length. Analogously, by a polypeptide having an aminoacid sequence having at least, for example, 95% identity to a referenceamino acid sequence of SEQ ID NO:2 is intended that the amino acidsequence of the polypeptide is identical to the reference sequenceexcept that the polypeptide sequence may include up to five amino acidalterations per each 100 amino acids of the reference amino acid of SEQID NO: 2. In other words, to obtain a polypeptide having an amino acidsequence at least 95% identical to a reference amino acid sequence, upto 5% of the amino acid residues in the reference sequence may bedeleted or substituted with another amino acid, or a number of aminoacids up to 5% of the total amino acid residues in the referencesequence may be inserted into the reference sequence. These alterationsof the reference sequence may occur at the amino or carboxy terminalpositions of the reference amino acid sequence or anywhere between thoseterminal positions, interspersed either individually among residues inthe reference sequence or in one or more contiguous groups within thereference sequence.

"Isolated" means altered "by the hand of man" from its natural state,i.e., if it occurs in nature, it has been changed or removed from itsoriginal environment, or both. For example, a polynucleotide or apolypeptide naturally present in a living organism is not "isolated,"but the same polynucleotide or polypeptide separated from the coexistingmaterials of its natural state is "isolated", as the term is employedherein.

"Polynucleotide(s)" generally refers to any polyribonucleotide orpolydeoxribonucleotide, which may be unmodified RNA or DNA or modifiedRNA or DNA. "Polynucleotide(s)" include, without limitation, single- anddouble-stranded DNA, DNA that is a mixture of single- anddouble-stranded regions or single-, double- and triple-stranded regions,single- and double-stranded RNA, and RNA that is mixture of single- anddouble-stranded regions, hybrid molecules comprising DNA and RNA thatmay be single-stranded or, more typically, double-stranded, ortriple-stranded regions, or a mixture of single- and double-strandedregions. In addition, "polynucleotide" as used herein refers totriple-stranded regions comprising RNA or DNA or both RNA and DNA. Thestrands in such regions may be from the same molecule or from differentmolecules. The regions may include all of one or more of the molecules,but more typically involve only a region of some of the molecules. Oneof the molecules of a triple-helical region often is an oligonucleotide.As used herein, the term "polynucleotide(s)" also includes DNAs or RNAsas described above that contain one or more modified bases. Thus, DNAsor RNAs with backbones modified for stability or for other reasons are"polynucleotide(s)" as that term is intended herein. Moreover, DNAs orRNAs comprising unusual bases, such as inosine, or modified bases, suchas tritylated bases, to name just two examples, are polynucleotides asthe term is used herein. It will be appreciated that a great variety ofmodifications have been made to DNA and RNA that serve many usefulpurposes known to those of skill in the art. The term"polynucleotide(s)" as it is employed herein embraces such chemically,enzymatically or metabolically modified forms of polynucleotides, aswell as the chemical forms of DNA and RNA characteristic of viruses andcells, including, for example, simple and complex cells."Polynucleotide(s)" also embraces short polynucleotides often referredto as oligonucleotide(s).

"Polypeptide(s)" refers to any peptide or protein comprising two or moreamino acids joined to each other by peptide bonds or modified peptidebonds. "Polypeptide(s)" refers to both short chains, commonly referredto as peptides, oligopeptides and oligomers and to longer chainsgenerally referred to as proteins. Polypeptides may contain amino acidsother than the 20 gene encoded amino acids. "Polypeptide(s)" includethose modified either by natural processes, such as processing and otherpost-translational modifications, but also by chemical modificationtechniques. Such modifications are well described in basic texts and inmore detailed monographs, as well as in a voluminous researchliterature, and they are well known to those of skill in the art. Itwill be appreciated that the same type of modification may be present inthe same or varying degree at several sites in a given polypeptide.Also, a given polypeptide may contain many types of modifications.Modifications can occur anywhere in a polypeptide, including the peptidebackbone, the amino acid side-chains, and the amino or carboxyl termini.Modifications include, for example, acetylation, acylation,ADP-ribosylation, amidation, covalent attachment of flavin, covalentattachment of a heme moiety, covalent attachment of a nucleotide ornucleotide derivative, covalent attachment of a lipid or lipidderivative, covalent attachment of phosphotidylinositol, cross-linking,cyclization, disulfide bond formation, demethylation, formation ofcovalent cross-links, formation of cysteine, formation of pyroglutamate,formylation, gamma-carboxylation, glycosylation, GPI anchor formation,hydroxylation, iodination, methylation, myristoylation, oxidation,proteolytic processing, phosphorylation, prenylation, racemization,glycosylation, lipid attachment, sulfation, gamma-carboxylation ofglutamic acid residues, hydroxylation and ADP-ribosylation,selenoylation, sulfation, transfer-RNA mediated addition of amino acidsto proteins, such as arginylation, and ubiquitination. See, forinstance, PROTEINS--STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E.Creighton, W. H. Freeman and Company, New York (1993) and Wold, F.,Posttranslational Protein Modifications: Perspectives and Prospects,pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C.Johnson, Ed., Academic Press, New York (1983); Seifter et al., Meth.Enzymol. 182:626-646 (1990) and Rattan et al., Protein Synthesis:Posttranslational Modifications and Aging, Ann. N.Y. Acad. Sci. 663:48-62 (1992). Polypeptides may be branched or cyclic, with or withoutbranching. Cyclic, branched and branched circular polypeptides mayresult from post-translational natural processes and may be made byentirely synthetic methods, as well.

"Variant(s)" as the term is used herein, is a polynucleotide orpolypeptide that differs from a reference polynucleotide or polypeptiderespectively, but retains essential properties. A typical variant of apolynucleotide differs in nucleotide sequence from another, referencepolynucleotide. Changes in the nucleotide sequence of the variant may ormay not alter the amino acid sequence of a polypeptide encoded by thereference polynucleotide. Nucleotide changes may result in amino acidsubstitutions, additions, deletions, fusions and truncations in thepolypeptide encoded by the reference sequence, as discussed below. Atypical variant of a polypeptide differs in amino acid sequence fromanother, reference polypeptide. Generally, differences are limited sothat the sequences of the reference polypeptide and the variant areclosely similar overall and, in many regions, identical. A variant andreference polypeptide may differ in amino acid sequence by one or moresubstitutions, additions, deletions in any combination. A substituted orinserted amino acid residue may or may not be one encoded by the geneticcode. A variant of a polynucleotide or polypeptide may be a naturallyoccurring such as an allelic variant, or it may be a variant that is notknown to occur naturally. Non-naturally occurring variants ofpolynucleotides and polypeptides may be made by mutagenesis techniques,by direct synthesis, and by other recombinant methods known to skilledartisans.

DESCRIPTION OF THE INVENTION

The invention relates to novel Era polypeptides and polynucleotides asdescribed in greater detail below. In particular, the invention relatesto polypeptides and polynucleotides of a novel Era of Streptococcuspneumoniae, which is related by amino acid sequence homology toStreptococcus mutans spg polypeptide (SWISS-PROT: locus ERA₋₋ STRMU,accession P37214). The invention relates especially to Era having thenucleotide and amino acid sequences set out in Table 1 [SEQ ID NO: 1]and Table 1 [SEQ ID NO: 2] respectively, and to the Era nucleotidesequences of the DNA in the deposited strain and amino acid sequencesencoded thereby.

                                      TABLE 1                                     __________________________________________________________________________    era Polynucleotide and Polypeptide Sequences                                  __________________________________________________________________________    (A) Sequences from Streptococcus pneumoniae Era polynucleotide                  sequence [SEQ ID NO:1].                                                     5'-1  ATGACTTTTA AATCAGGCTT TGTAGCCATT TTAGGACGTC CCAATGTTGG                     - 51 GAAGTCAACC TTTTTAAATC ACGTTATGGG GCAAAAGATT GCCATCATGA                   - 101 GTGACAAGGC GCAGACAACG CGCAATAAAA TCATGGGAAT TTACACGACT                  - 151 GATAAGGAGC AAATTGTCTT TATCGACACA CCAGGGATTC ACAAACCTAA                  - 201 AACAGCTCTC GGAGATTTCA TGGTTGAGTC TGCCTACAGT ACCCTTCGCG                  - 251 AAGTGGACAC TGTTCTTTTC ATGGTGCCTG CTGATGAAGC GCGTGGTAAG                  - 301 GGGGACGATA TGATTATCGA GCGTCTCAAG GCTGCCAAGG TTCCTGTGAT                  - 351 TTTGGTGGTG AATAAAATCG ATAAGGTCCA TCCAGACCAG CTCTTGTCTC                  - 401 AGATTGATGA CTTCCGTAAT CAAATGGACT TTAAGGAAAT TGTTCCAATC                  - 451 TCAGCCCTTC AGGGAAATAA CGTGTCTCGT CTAGTGGATA TTTTGAGTGA                  - 501 AAATCTGGAT GAAGGTTTCC AATATTTCCC GTCTGATCAA ATCACAGACC                  - 551 ATCCAGAACG TTTCTTAGTT TCAGAAATGG TTCGCGAGAA AGTCTTGCAC                  - 601 CTAACTCGTG AAGAGATTCC GCATTCTGTA GCAGTAGTTG TTGACTCTAT                  - 651 GAAACGAGAC GAAGAGACAG ACAAGGTTCA CATCCGTGCA ACCATCATGG                  - 701 TCGAGCGCGA TAGCCAAAAA GGGATTATCA TCGGTAAAGG TGGCGCTATG                  - 751 CTTAAGAAAA TCGGTAGCAT GGCCCGTCGT GATATCGAAC TCATGCTAGG                  - 801 AGACAAGGTC TTCCTAGAAA CCTGGGTCAA GGTCAAGAAA AACTGGCGCG                  - 851 ATAAAAAGCT AGATTTGGCT GACTTGGGCT ATAATGAAAG AGAATACTAA -3'                   -                                                                     (B) Era polypeptide sequence deduced from the polynucleotide                    sequence in this table [SEQ ID NO:2].                                       NH.sub.2 -1                                                                         MTFKSGFVAI LGRPNVGKST FLNHVMGQKI AIMSDKAQTT RNKIMGIYTT                     - 51 DKEQIVFIDT PGIHKPKTAL GDFMVESAYS TLREVDTVLF MVPADEARGK                   - 101 GDDMIIERLK AAKVPVILVV NKIDKVHPDQ LLSQIDDFRN QMDFKEIVPI                  - 151 SALQGNNVSR LVDILSENLD EGFQYFPSDQ ITDHPERFLV SEMVREKVLH                  - 201 LTREEIPHSV AVVVDSMKRD EETDKVHIRA TIMVERDSQK GIIIGKGGAM                  - 251 LKKIGSMARR DIELMLGDKV FLETWVKVKK NWRDKKLDLA DLGYNEREY -COOH                  -                                                                     (C) Polynucleotide sequence embodiments [SEQ ID NO:1].                        X-(R.sub.1).sub.n -1                                                                ATGACTTTTA AATCAGGCTT TGTAGCCATT TTAGGACGTC CCAATGTTGG                     - 51 GAAGTCAACC TTTTTAAATC ACGTTATGGG GCAAAAGATT GCCATCATGA                   - 101 GTGACAAGGC GCAGACAACG CGCAATAAAA TCATGGGAAT TTACACGACT                  - 151 GATAAGGAGC AAATTGTCTT TATCGACACA CCAGGGATTC ACAAACCTAA                  - 201 AACAGCTCTC GGAGATTTCA TGGTTGAGTC TGCCTACAGT ACCCTTCGCG                  - 251 AAGTGGACAC TGTTCTTTTC ATGGTGCCTG CTGATGAAGC GCGTGGTAAG                  - 301 GGGGACGATA TGATTATCGA GCGTCTCAAG GCTGCCAAGG TTCCTGTGAT                  - 351 TTTGGTGGTG AATAAAATCG ATAAGGTCCA TCCAGACCAG CTCTTGTCTC                  - 401 AGATTGATGA CTTCCGTAAT CAAATGGACT TTAAGGAAAT TGTTCCAATC                  - 451 TCAGCCCTTC AGGGAAATAA CGTGTCTCGT CTAGTGGATA TTTTGAGTGA                  - 501 AAATCTGGAT GAAGGTTTCC AATATTTCCC GTCTGATCAA ATCACAGACC                  - 551 ATCCAGAACG TTTCTTAGTT TCAGAAATGG TTCGCGAGAA AGTCTTGCAC                  - 601 CTAACTCGTG AAGAGATTCC GCATTCTGTA GCAGTAGTTG TTGACTCTAT                  - 651 GAAACGAGAC GAAGAGACAG ACAAGGTTCA CATCCGTGCA ACCATCATGG                  - 701 TCGAGCGCGA TAGCCAAAAA GGGATTATCA TCGGTAAAGG TGGCGCTATG                  - 751 CTTAAGAAAA TCGGTAGCAT GGCCCGTCGT GATATCGAAC TCATGCTAGG                  - 801 AGACAAGGTC TTCCTAGAAA CCTGGGTCAA GGTCAAGAAA AACTGGCGCG                  - 851 ATAAAAAGCT AGATTTGGCT GACTTGGGCT ATAATGAAAG AGAATACTAA                  - -(R.sub.2).sub.n -Y                                                         -                                                                          (D) Polypeptide sequence embodiments [SEQ ID NO:2].                           X-(R.sub.1).sub.n -1                                                                MTFKSGFVAI LGRPNVGKST FLNHVMGQKI AIMSDKAQTT RNKIMGIYTT                     - 51 DKEQIVFIDT PGIHKPKTAL GDFMVESAYS TLREVDTVLF MVPADEARGK                   - 101 GDDMIIERLK AAKVPVILVV NKIDKVHPDQ LLSQIDDFRN QMDFKEIVPI                  - 151 SALQGNNVSR LVDILSENLD EGFQYFPSDQ ITDHPERFLV SEMVREKVLH                  - 201 LTREEIPHSV AVVVDSMKRD EETDKVHIRA TIMVERDSQK GIIIGKGGAM                  - 251 LKKIGSMARR DIELMLGDKV FLETWVKVKK NWRDKKLDLA DLGYNEREY                   - -(R.sub.2).sub.n -Y                                                      __________________________________________________________________________

Deposited materials

A deposit containing a Streptococcus pneumoniae 0100993 strain has beendeposited with the National Collections of Industrial and MarineBacteria Ltd. (herein "NCIMB"), 23 St. Machar Drive, Aberdeen AB2 1RY,Scotland on Apr. 11, 1996 and assigned deposit number 40794. The depositwas described as Streptococcus pneumoniae 0100993 on deposit. On Apr.17, 1996 a Streptococcus pneumoniae 0100993 DNA library in E. coli wassimilarly deposited with the NCIMB and assigned deposit number 40800.The Streptococcus pneumoniae strain deposit is referred to herein as"the deposited strain" or as "the DNA of the deposited strain."

The deposited strain contains the full length era gene. The sequence ofthe polynucleotides contained in the deposited strain, as well as theamino acid sequence of the polypeptide encoded thereby, are controllingin the event of any conflict with any description of sequences herein.

The deposit of the deposited strain has been made under the terms of theBudapest Treaty on the International Recognition of the Deposit ofMicro-organisms for Purposes of Patent Procedure. The strain will beirrevocably and without restriction or condition released to the publicupon the issuance of a patent. The deposited strain is provided merelyas convenience to those of skill in the art and is not an admission thata deposit is required for enablement, such as that required under 35U.S.C. §112.

A license may be required to make, use or sell the deposited strain, andcompounds derived therefrom, and no such license is hereby granted.

Polypeptides

The polypeptides of the invention include the polypeptide of Table 1[SEQ ID NO:2] (in particular the mature polypeptide) as well aspolypeptides and fragments, particularly those which have the biologicalactivity of Era, and also those which have at least 92% identity to thepolypeptide of Table 1 [SEQ ID NO:2] or the relevant portion, preferablyat least 95% identity to the polypeptide of Table 1 [SEQ ID NO:2], morepreferably at least 97% similarity (more preferably at least 97.5%identity) to the polypeptide of Table 1 [SEQ ID NO:2], and morepreferably at least 98% similarity (more preferably at least 98%identity) to the polypeptide of Table 1 [SEQ ID NO:2] and still morepreferably at least 99% similarity (still more preferably at least 99%identity) to the polypeptide of Table 1 [SEQ ID NO:2] and also includeportions of such polypeptides with such portion of the polypeptidegenerally containing at least 30 amino acids and more preferably atleast 50 amino acids.

The invention also includes polypeptides of the formula set forth inTable 1 (D) wherein, at the amino terminus, X is hydrogen, and at thecarboxyl terminus, Y is hydrogen or a meal, R₁ and R₂ is any amino acidresidue, and n is an integer between 1 and 1000. Any stretch of aminoacid residues denoted by either R group, where R is greater than 1, maybe either a heteropolymer or a homopolymer, preferably a heteropolymer.

A fragment is a variant polypeptide having an amino acid sequence thatentirely is the same as part but not all of the amino acid sequence ofthe aforementioned polypeptides. As with Era polypeptides fragments maybe "free-standing," or comprised within a larger polypeptide of whichthey form a part or region, most preferably as a single continuousregion, a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides havinga portion of the amino acid sequence of Table 1 [SEQ ID NO:2], or ofvariants thereof, such as a continuous series of residues that includesthe amino terminus, or a continuous series of residues that includes thecarboxyl terminus. Degradation forms of the polypeptides of theinvention in a host cell, particularly a Streptococcus pneumoniae, arealso preferred. Further preferred are fragments characterized bystructural or functional attributes such as fragments that comprisealpha-helix and alpha-helix forming regions, beta-sheet andbeta-sheet-forming regions, turn and turn-forming regions, coil andcoil-forming regions, hydrophilic regions, hydrophobic regions, alphaamphipathic regions, beta amphipathic regions, flexible regions,surface-forming regions, substrate binding region, and high antigenicindex regions.

Also preferred are biologically active fragments which are thosefragments that mediate activities of Era, including those with a similaractivity or an improved activity, or with a decreased undesirableactivity. Also included are those fragments that are antigenic orimmunogenic in an animal, especially in a human. Particularly preferredare fragments comprising receptors or domains of enzymes that confer afunction essential for viability of Streptococcus pneumoniae or theability to initiate, or maintain cause disease in an individual,particularly a human.

Variants that are fragments of the polypeptides of the invention may beemployed for producing the corresponding full-length polypeptide bypeptide synthesis; therefore, these variants may be employed asintermediates for producing the full-length polypeptides of theinvention.

Polynucleotides

Another aspect of the invention relates to isolated polynucleotides,including the full length gene, that encode the era polypeptide havingthe deduced amino acid sequence of Table 1 [SEQ ID NO:2] andpolynucleotides closely related thereto and variants thereof.

Using the information provided herein, such as the polynucleotidesequence set out in Table 1 [SEQ ID NO:1], a polynucleotide of theinvention encoding Era polypeptide may be obtained using standardcloning and screening methods, such as those for cloning and sequencingchromosomal DNA fragments from bacteria using Streptococcus pneumoniae0100993 cells as starting material, followed by obtaining a full lengthclone. For example, to obtain a polynucleotide sequence of theinvention, such as the sequence given in Table 1 [SEQ ID NO:1],typically a library of clones of chromosomal DNA of Streptococcuspneumoniae 0100993 in E.coli or some other suitable host is probed witha radiolabeled oligonucleotide, preferably a 17-mer or longer, derivedfrom a partial sequence. Clones carrying DNA identical to that of theprobe can then be distinguished using stringent conditions. Bysequencing the individual clones thus identified with sequencing primersdesigned from the original sequence it is then possible to extend thesequence in both directions to determine the full gene sequence.Conveniently, such sequencing is performed using denatured doublestranded DNA prepared from a plasmid clone. Suitable techniques aredescribed by Maniatis, T., Fritsch, E. F. and Sambrook et al., MOLECULARCLONING, A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y. (1989). (see in particular Screening ByHybridization 1.90 and Sequencing Denatured Double-Stranded DNATemplates 13.70). Illustrative of the invention, the polynucleotide setout in Table 1 [SEQ ID NO:1] was discovered in a DNA library derivedfrom Streptococcus pneumoniae 0100993.

The DNA sequence set out in Table 1 [SEQ ID NO:1] contains an openreading frame encoding a protein having about the number of amino acidresidues set forth in Table 1 [SEQ ID NO:2] with a deduced molecularweight that can be calculated using amino acid residue molecular weightvalues well known in the art. The polynucleotide of SEQ ID NO: 1,between nucleotide number 1 through number 897 encodes the polypeptideof SEQ ID NO:2. The stop codon begins at nucleotide number 898 of SEQ IDNO:1.

The Era polypeptide of the invention is structurally related to otherproteins of the Era-type GTPases family, as shown by the results ofsequencing the DNA encoding Era of the deposited strain. The proteinexhibits greatest homology to Streptococcus mutans spg protein amongknown proteins. Era of Table 1 [SEQ ID NO:2] has about 91.6% identityover its entire length and about 96.0% similarity over its entire lengthwith the amino acid sequence of Streptococcus mutans spg polypeptide.

The invention provides a polynucleotide sequence identical over itsentire length to the coding sequence in Table 1 [SEQ ID NO:1]. Alsoprovided by the invention is the coding sequence for the maturepolypeptide or a fragment thereof, by itself as well as the codingsequence for the mature polypeptide or a fragment in reading frame withother coding sequence, such as those encoding a leader or secretorysequence, a pre-, or pro- or prepro-protein sequence. The polynucleotidemay also contain non-coding sequences, including for example, but notlimited to non-coding 5' and 3' sequences, such as the transcribed,non-translated sequences, termination signals, ribosome binding sites,sequences that stabilize mRNA, introns, polyadenylation signals, andadditional coding sequence which encode additional amino acids. Forexample, a marker sequence that facilitates purification of the fusedpolypeptide can be encoded. In certain embodiments of the invention, themarker sequence is a hexa-histidine peptide, as provided in the pQEvector (Qiagen, Inc.) and described in Gentz et al., Proc. Natl. Acad.Sci., USA 86: 821-824 (1989), or an HA tag (Wilson et al., Cell 37: 767(1984). Polynucleotides of the invention also include, but are notlimited to, polynucleotides comprising a structural gene and itsnaturally associated sequences that control gene expression.

A preferred embodiment of the invention is the polynucleotide ofcomprising nucleotide 1 to 897 set forth in SEQ ID NO:1 of Table 1 whichencodes the Era polypeptide.

The invention also includes polynucleotides of the formula set forth inTable 1 (C) wherein, at the 5' end of the molecule, X is hydrogen, andat the 3' end of the molecule, Y is hydrogen or a metal, R₁ and R₂ isany nucleic acid residue, and n is an integer between 1 and 1000. Anystretch of nucleic acid residues denoted by either R group, where R isgreater than 1, may be either a heteropolymer or a homopolymer,preferably a heteropolymer.

The term "polynucleotide encoding a polypeptide" as used hereinencompasses polynucleotides that include a sequence encoding apolypeptide of the invention, particularly a bacterial polypeptide andmore particularly a polypeptide of the Streptococcus pneumoniae Erahaving the amino acid sequence set out in Table 1 [SEQ ID NO:2]. Theterm also encompasses polynucleotides that include a single continuousregion or discontinuous regions encoding the polypeptide (for example,interrupted by integrated phage or an insertion sequence or editing)together with additional regions, that also may contain coding and/ornon-coding sequences.

The invention further relates to variants of the polynucleotidesdescribed herein that encode for variants of the polypeptide having thededuced amino acid sequence of Table 1 [SEQ ID NO:2]. Variants that arefragments of the polynucleotides of the invention may be used tosynthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encodingEra variants, that have the amino acid sequence of Era polypeptide ofTable 1 [SEQ ID NO:2] in which several, a few, 5 to 10, 1 to 5, 1 to 3,2, 1 or no amino acid residues are substituted, deleted or added, in anycombination. Especially preferred among these are silent substitutions,additions and deletions, that do not alter the properties and activitiesof Era.

Further preferred embodiments of the invention are polynucleotides thatare at least 70% identical over their entire length to a polynucleotideencoding Era polypeptide having the amino acid sequence set out in Table1 [SEQ ID NO:2], and polynucleotides that are complementary to suchpolynucleotides. Alternatively, most highly preferred arepolynucleotides that comprise a region that is at least 80% identicalover its entire length to a polynucleotide encoding Era polypeptide ofthe deposited strain and polynucleotides complementary thereto. In thisregard, polynucleotides at least 90% identical over their entire lengthto the same are particularly preferred, and among these particularlypreferred polynucleotides, those with at least 95% are especiallypreferred. Furthermore, those with at least 97% are highly preferredamong those with at least 95%, and among these those with at least 98%and at least 99% are particularly highly preferred, with at least 99%being the more preferred.

Preferred embodiments are polynucleotides that encode polypeptides thatretain substantially the same biological function or activity as themature polypeptide encoded by the DNA of Table 1 [SEQ ID NO:1].

The invention further relates to polynucleotides that hybridize to theherein above-described sequences. In this regard, the inventionespecially relates to polynucleotides that hybridize under stringentconditions to the herein above-described polynucleotides. As hereinused, the terms "stringent conditions" and "stringent hybridizationconditions" mean hybridization will occur only if there is at least 95%and preferably at least 97% identity between the sequences. An exampleof stringent hybridization conditions is overnight incubation at 42° C.in a solution comprising: 50% formamide, 5× SSC (150 mM NaCl, 15 mMtrisodium citrate), 50 mM sodium phosphate (pH7.6), 5× Denhardt'ssolution, 10% dextran sulfate, and 20 micrograms/ml denatured, shearedsalmon sperm DNA, followed by washing the hybridization support in 0.1×SSC at about 65° C. Hybridization and wash conditions are well known andexemplified in Sambrook, et al., Molecular Cloning: A Laboratory Manual,Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter11 therein.

The invention also provides a polynucleotide consisting essentially of apolynucleotide sequence obtainable by screening an appropriate librarycontaining the complete gene for a polynucleotide sequence set forth inSEQ ID NO:1 under stringent hybridization conditions with a probe havingthe sequence of said polynucleotide sequence set forth in SEQ ID NO:1 ora fragment thereof; and isolating said DNA sequence. Fragments usefulfor obtaining such a polynucleotide include, for example, probes andprimers described elsewhere herein.

As discussed additionally herein regarding polynucleotide assays of theinvention, for instance, polynucleotides of the invention as discussedabove, may be used as a hybridization probe for RNA, cDNA and genomicDNA to isolate full-length cDNAs and genomic clones encoding Era and toisolate cDNA and genomic clones of other genes that have a high sequencesimilarity to the era gene. Such probes generally will comprise at least15 bases. Preferably, such probes will have at least 30 bases and mayhave at least 50 bases. Particularly preferred probes will have at least30 bases and will have 50 bases or less.

For example, the coding region of the era gene may be isolated byscreening using the DNA sequence provided in SEQ ID NO: 1 to synthesizean oligonucleotide probe. A labeled oligonucleotide having a sequencecomplementary to that of a gene of the invention is then used to screena library of cDNA, genomic DNA or mRNA to determine which members of thelibrary the probe hybridizes to.

The polynucleotides and polypeptides of the invention may be employed,for example, as research reagents and materials for discovery oftreatments of and diagnostics for disease, particularly human disease,as further discussed herein relating to polynucleotide assays.

Polynucleotides of the invention that are oligonucleotides derived fromthe sequences of SEQ ID NOS:1 and/or 2 may be used in the processesherein as described, but preferably for PCR, to determine whether or notthe polynucleotides identified herein in whole or in part aretranscribed in bacteria in infected tissue. It is recognized that suchsequences will also have utility in diagnosis of the stage of infectionand type of infection the pathogen has attained.

The invention also provides polynucleotides that may encode apolypeptide that is the mature protein plus additional amino orcarboxyl-terminal amino acids, or amino acids interior to the maturepolypeptide (when the mature form has more than one polypeptide chain,for instance). Such sequences may play a role in processing of a proteinfrom precursor to a mature form, may allow protein transport, maylengthen or shorten protein half-life or may facilitate manipulation ofa protein for assay or production, among other things. As generally isthe case in vivo, the additional amino acids may be processed away fromthe mature protein by cellular enzymes.

A precursor protein, having the mature form of the polypeptide fused toone or more prosequences may be an inactive form of the polypeptide.When prosequences are removed such inactive precursors generally areactivated. Some or all of the prosequences may be removed beforeactivation. Generally, such precursors are called proproteins.

In sum, a polynucleotide of the invention may encode a mature protein, amature protein plus a leader sequence (which may be referred to as apreprotein), a precursor of a mature protein having one or moreprosequences that are not the leader sequences of a preprotein, or apreproprotein, which is a precursor to a proprotein, having a leadersequence and one or more prosequences, which generally are removedduring processing steps that produce active and mature forms of thepolypeptide.

Vectors, host cells, expression

The invention also relates to vectors that comprise a polynucleotide orpolynucleotides of the invention, host cells that are geneticallyengineered with vectors of the invention and the production ofpolypeptides of the invention by recombinant techniques. Cell-freetranslation systems can also be employed to produce such proteins usingRNAs derived from the DNA constructs of the invention.

For recombinant production, host cells can be genetically engineered toincorporate expression systems or portions thereof or polynucleotides ofthe invention. Introduction of a polynucleotide into the host cell canbe effected by methods described in many standard laboratory manuals,such as Davis et al., BASIC METHODS IN MOLECULAR BIOLOGY, (1986) andSambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed, ColdSpring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), suchas, calcium phosphate transfection, DEAE-dextran mediated transfection,transvection, microinjection, cationic lipid-mediated transfection,electroporation, transduction, scrape loading, ballistic introductionand infection.

Representative examples of appropriate hosts include bacterial cells,such as streptococci, staphylococci, enterococci E. coli, streptomycesand Bacillus subtilis cells; fungal cells, such as yeast cells andAspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 andBowes melanoma cells; and plant cells.

A great variety of expression systems can be used to produce thepolypeptides of the invention. Such vectors include, among others,chromosomal, episomal and virus-derived vectors, e.g., vectors derivedfrom bacterial plasmids, from bacteriophage, from tansposons, from yeastepisomes, from insertion elements, from yeast chromosomal elements, fromviruses such as baculoviruses, papova viruses, such as SV40, vacciniaviruses, adenoviruses, fowl pox viruses, pseudorabies viruses andretroviruses, and vectors derived from combinations thereof, such asthose derived from plasmid and bacteriophage genetic elements, such ascosmids and phagemids. The expression system constructs may containcontrol regions that regulate as well as engender expression. Generally,any system or vector suitable to maintain, propagate or expresspolynucleotides and/or to express a polypeptide in a host may be usedfor expression in this regard. The appropriate DNA sequence may beinserted into the expression system by any of a variety of well-knownand routine techniques, such as, for example, those set forth inSambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, (supra).

For secretion of the translated protein into the lumen of theendoplasmic reticulum, into the periplasmic space or into theextracellular environment, appropriate secretion signals may beincorporated into the expressed polypeptide. These signals may beendogenous to the polypeptide or they may be heterologous signals.

Polypeptides of the invention can be recovered and purified fromrecombinant cell cultures by well-known methods including ammoniumsulfate or ethanol precipitation, acid extraction, anion or cationexchange chromatography, phosphocellulose chromatography, hydrophobicinteraction chromatography, affinity chromatography, hydroxylapatitechromatography, and lectin chromatography. Most preferably, highperformance liquid chromatography is employed for purification. Wellknown techniques for refolding protein may be employed to regenerateactive conformation when the polypeptide is denatured during isolationand or purification.

Diagnostic Assays

This invention is also related to the use of the era polynucleotides ofthe invention for use as diagnostic reagents. Detection of era in aeukaryote, particularly a mammal, and especially a human, will provide adiagnostic method for diagnosis of a disease. Eukaryotes (herein also"individual(s)"), particularly mammals, and especially humans,particularly those infected or suspected to be infected with an organismcomprising the era gene may be detected at the nucleic acid level by avariety of techniques.

Nucleic acids for diagnosis may be obtained from an infectedindividual's cells and tissues, such as bone, blood, muscle, cartilage,and skin. Genomic DNA may be used directly for detection or may beamplified enzymatically by using PCR or other amplification techniqueprior to analysis. RNA or cDNA may also be used in the same ways. Usingamplification, characterization of the species and strain of prokaryotepresent in an individual, may be made by an analysis of the genotype ofthe prokaryote gene. Deletions and insertions can be detected by achange in size of the amplified product in comparison to the genotype ofa reference sequence. Point mutations can be identified by hybridizingamplified DNA to labeled era polynucleotide sequences. Perfectly matchedsequences can be distinguished from mismatched duplexes by RNasedigestion or by differences in melting temperatures. DNA sequencedifferences may also be detected by alterations in the electrophoreticmobility of the DNA fragments in gels, with or without denaturingagents, or by direct DNA sequencing. See, e.g., Myers et al., Science,230: 1242 (1985). Sequence changes at specific locations also may berevealed by nuclease protection assays, such as RNase and S1 protectionor a chemical cleavage method. See, e.g., Cotton et al., Proc. Natl.Acad. Sci., USA, 85: 4397-4401 (1985).

Cells carrying mutations or polymorphisms in the gene of the inventionmay also be detected at the DNA level by a variety of techniques, toallow for serotyping, for example. For example, RT-PCR can be used todetect mutations. It is particularly preferred to used RT-PCR inconjunction with automated detection systems, such as, for example,GeneScan. RNA or cDNA may also be used for the same purpose, PCR orRT-PCR. As an example, PCR primers complementary to a nucleic acidencoding Era can be used to identify and analyze mutations.

The invention further provides these primers with 1, 2, 3 or 4nucleotides removed from the 5' and/or the 3' end. These primers may beused for, among other things, amplifying Era DNA isolated from a samplederived from an individual. The primers may be used to amplify the geneisolated from an infected individual such that the gene may then besubject to various techniques for elucidation of the DNA sequence. Inthis way, mutations in the DNA sequence may be detected and used todiagnose infection and to serotype and/or classify the infectious agent.

The invention further provides a process for diagnosing, disease,preferably bacterial infections, more preferably infections byStreptococcus pneumoniae, and most preferably otitis media,conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleuralempyema and endocarditis, and most particularly meningitis, such as forexample infection of cerebrospinal fluid, comprising determining from asample derived from an individual a increased level of expression ofpolynucleotide having the sequence of Table 1 [SEQ ID NO: 1]. Increasedor decreased expression of Era polynucleotide can be measured using anyon of the methods well known in the art for the quantation ofpolynucleotides, such as, for example, amplification, PCR, RT-PCR, RNaseprotection, Northern blotting and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention fordetecting over-expression of Era protein compared to normal controltissue samples may be used to detect the presence of an infection, forexample. Assay techniques that can be used to determine levels of a eraprotein, in a sample derived from a host are well-known to those ofskill in the art. Such assay methods include radioimmunoassays,competitive-binding assays, Western Blot analysis and ELISA assays.

Antibodies

The polypeptides of the invention or variants thereof, or cellsexpressing them can be used as an immunogen to produce antibodiesimmunospecific for such polypeptides. "Antibodies" as used hereinincludes monoclonal and polyclonal antibodies, chimeric, single chain,simianized antibodies and humanized antibodies, as well as Fabfragments, including the products of an Fab immunolglobulin expressionlibrary.

Antibodies generated against the polypeptides of the invention can beobtained by administering the polypeptides or epitope-bearing fragments,analogues or cells to an animal, preferably a nonhuman, using routineprotocols. For preparation of monoclonal antibodies, any technique knownin the art that provides antibodies produced by continuous cell linecultures can be used. Examples include various techniques, such as thosein Kohler, G. and Milstein, C., Nature 256: 495-497 (1975); Kozbor etal., Immunology Today 4: 72 (1983); Cole et al., pg. 77-96 in MONOCLONALANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc. (1985).

Techniques for the production of single chain antibodies (U.S. Pat. No.4,946,778) can be adapted to produce single chain antibodies topolypeptides of this invention. Also, transgenic mice, or otherorganisms such as other mammals, may be used to express humanizedantibodies.

Alternatively phage display technology may be utilized to selectantibody genes with binding activities towards the polypeptide eitherfrom repertoires of PCR amplified v-genes of lymphocytes from humansscreened for possessing anti-era or from naive libraries (McCafferty, J.et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992)Biotechnology 10, 779-783). The affinity of these antibodies can also beimproved by chain shuffling (Clackson, T. et al., (1991) Nature 352,624-628).

If two antigen binding domains are present each domain may be directedagainst a different epitope--termed `bispecific` antibodies.

The above-described antibodies may be employed to isolate or to identifyclones expressing the polypeptides to purify the polypeptides byaffinity chromatography.

Thus, among others, antibodies against Era-polypeptide may be employedto treat infections, particularly bacterial infections and especiallyotitis media, conjunctivitis, pneumonia, bacteremia, meningitis,sinusitis, pleural empyema and endocarditis, and most particularlymeningitis, such as for example infection of cerebrospinal fluid.

Polypeptide variants include antigenically, epitopically orimmunologically equivalent variants that form a particular aspect ofthis invention. The term "antigenically equivalent derivative" as usedherein encompasses a polypeptide or its equivalent which will bespecifically recognized by certain antibodies which, when raised to theprotein or polypeptide according to the invention, interfere with theimmediate physical interaction between pathogen and mammalian host. Theterm "immunologically equivalent derivative" as used herein encompassesa peptide or its equivalent which when used in a suitable formulation toraise antibodies in a vertebrate, the antibodies act to interfere withthe immediate physical interaction between pathogen and mammalian host.

The polypeptide, such as an antigenically or immunologically equivalentderivative or a fusion protein thereof is used as an antigen to immunizea mouse or other animal such as a rat or chicken. The fusion protein mayprovide stability to the polypeptide. The antigen may be associated, forexample by conjugation, with an immunogenic carrier protein for examplebovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH).Alternatively a multiple antigenic peptide comprising multiple copies ofthe protein or polypeptide, or an antigenically or immunologicallyequivalent polypeptide thereof may be sufficiently antigenic to improveimmunogenicity so as to obviate the use of a carrier.

Preferably, the antibody or variant thereof is modified to make it lessimmunogenic in the individual. For example, if the individual is humanthe antibody may most preferably be "humanized"; where thecomplimentarity determining region(s) of the hybridoma-derived antibodyhas been transplanted into a human monoclonal antibody, for example asdescribed in Jones, P. et al. (1986), Nature 321, 522-525 or Tempest etal., (1991) Biotechnology 9, 266-273.

The use of a polynucleotide of the invention in genetic immunizationwill preferably employ a suitable delivery method such as directinjection of plasmid DNA into muscles (Wolff et al., Hum Mol Genet 1992,1:363, Manthorpe et al., Hum. Gene Ther. 1963:4, 419), delivery of DNAcomplexed with specific protein carriers (Wu et al., J Biol Chem. 1989:264,16985), coprecipitation of DNA with calcium phosphate (Benvenisty &Reshef, PNAS USA, 1986:83,9551), encapsulation of DNA in various formsof liposomes (Kaneda et al., Science 1989:243,375), particle bombardment(Tang et al., Nature 1992, 356:152, Eisenbraun et al., DNA Cell Biol1993, 12:791) and in vivo infection using cloned retroviral vectors(Seeger et al., PNAS USA 1984:81,5849).

Antagonists and agonists--assays and molecules

Polypeptides of the invention may also be used to assess the binding ofsmall molecule substrates and ligands in, for example, cells, cell-freepreparations, chemical libraries, and natural product mixtures. Thesesubstrates and ligands may be natural substrates and ligands or may bestructural or functional mimetics. See, e.g., Coligan et al., CurrentProtocols in Immunology 1(2): Chapter 5 (1991).

The invention also provides a method of screening compounds to identifythose which enhance (agonist) or block (antagonist) the action of Erapolypeptides or polynucleotides, particularly those compounds that arebacteriostatic and/or bactericidal. The method of screening may involvehigh-throughput techniques. For example, to screen for agonists orantagonists, a synthetic reaction mix, a cellular compartment, such as amembrane, cell envelope or cell wall, or a preparation of any thereof,comprising Era polypeptide and a labeled substrate or ligand of suchpolypeptide is incubated in the absence or the presence of a candidatemolecule that may be a Era agonist or antagonist. The ability of thecandidate molecule to agonize or antagonize the Era polypeptide isreflected in decreased binding of the labeled ligand or decreasedproduction of product from such substrate. Molecules that bindgratuitously, i.e., without inducing the effects of Era polypeptide aremost likely to be good antagonists. Molecules that bind well andincrease the rate of product production from substrate are agonists.Detection of the rate or level of production of product from substratemay be enhanced by using a reporter system. Reporter systems that may beuseful in this regard include but are not limited to colorimetriclabeled substrate converted into product, a reporter gene that isresponsive to changes in Era polynucleotide or polypeptide activity, andbinding assays known in the art.

Another example of an assay for Era antagonists is a competitive assaythat combines Era and a potential antagonist with Era-binding molecules,recombinant Era binding molecules, natural substrates or ligands, orsubstrate or ligand mimetics, under appropriate conditions for acompetitive inhibition assay. The Era molecule can be labeled, such asby radioactivity or a colorimetric compound, such that the number of Eramolecules bound to a binding molecule or converted to product can bedetermined accurately to assess the effectiveness of the potentialantagonist.

Potential antagonists include small organic molecules, peptides,polypeptides and antibodies that bind to a polynucleotide or polypeptideof the invention and thereby inhibit or extinguish its activity.Potential antagonists also may be small organic molecules, a peptide, apolypeptide such as a closely related protein or antibody that binds thesame sites on a binding molecule, such as a binding molecule, withoutinducing Era-induced activities, thereby preventing the action of Era byexcluding Era from binding.

Potential antagonists include a small molecule that binds to andoccupies the binding site of the polypeptide thereby preventing bindingto cellular binding molecules, such that normal biological activity isprevented. Examples of small molecules include but are not limited tosmall organic molecules, peptides or peptide-like molecules. Otherpotential antagonists include antisense molecules (see Okano, J.Neurochem. 56: 560 (1991); OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORSOF GENE EXPRESSION, CRC Press, Boca Raton, Fla. (1988), for adescription of these molecules). Preferred potential antagonists includecompounds related to and variants of Era.

Each of the DNA sequences provided herein may be used in the discoveryand development of antibacterial compounds. The encoded protein, uponexpression, can be used as target for the screening of antibacterialdrugs. Additionally, the DNA sequences encoding the amino terminalregions of the encoded protein or Shine-Delgarno or other translationfacilitating sequences of the respective mRNA can be used to constructantisense sequences to control the expression of the coding sequence ofinterest.

The invention also provides the use of the polypeptide, polynucleotideor inhibitor of the invention to interfere with the initial physicalinteraction between a pathogen and mammalian host responsible forsequelae of infection. In particular the molecules of the invention maybe used: in the prevention of adhesion of bacteria, in particular grampositive bacteria, to mammalian extracellular matrix proteins onin-dwelling devices or to extracellular matrix proteins in wounds; toblock Era protein-mediated mammalian cell invasion by, for example,initiating phosphorylation of mammalian tyrosine kinases (Rosenshine etal., Infect. Immun. 60:2211 (1992); to block bacterial adhesion betweenmammalian extracellular matrix proteins and bacterial Era proteins thatmediate tissue damage and; to block the normal progression ofpathogenesis in infections initiated other than by the implantation ofin-dwelling devices or by other surgical techniques.

The antagonists and agonists of the invention may be employed, forinstance, to inhibit and treat otitis media, conjunctivitis, pneumonia,bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, andmost particularly meningitis, such as for example infection ofcerebrospinal fluid.

Vaccines

Another aspect of the invention relates to a method for inducing animmunological response in an individual, particularly a mammal whichcomprises inoculating the individual with Era, or a fragment or variantthereof, adequate to produce antibody and/or T cell immune response toprotect said individual from infection, particularly bacterial infectionand most particularly Streptococcus pneumoniae infection. Also providedare methods whereby such immunological response slows bacterialreplication. Yet another aspect of the invention relates to a method ofinducing immunological response in an individual which comprisesdelivering to such individual a nucleic acid vector to direct expressionof Era, or a fragment or a variant thereof, for expressing Era, or afragment or a variant thereof in vivo in order to induce animmunological response, such as, to produce antibody and/or T cellimmune response, including, for example, cytokine-producing T cells orcytotoxic T cells, to protect said individual from disease, whether thatdisease is already established within the individual or not. One way ofadministering the gene is by accelerating it into the desired cells as acoating on particles or otherwise.

Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid,or a DNA/RNA hybrid.

A further aspect of the invention relates to an immunologicalcomposition which, when introduced into an individual capable or havinginduced within it an immunological response, induces an immunologicalresponse in such individual to a Era or protein coded therefrom, whereinthe composition comprises a recombinant Era or protein coded therefromcomprising DNA which codes for and expresses an antigen of said Era orprotein coded therefrom. The immunological response may be usedtherapeutically or prophylactically and may take the form of antibodyimmunity or cellular immunity such as that arising from CTL or CD4+ Tcells.

A Era polypeptide or a fragment thereof may be fused with co-proteinwhich may not by itself produce antibodies, but is capable ofstabilizing the first protein and producing a fused protein which willhave immunogenic and protective properties. Thus fused recombinantprotein, preferably further comprises an antigenic co-protein, such aslipoprotein D from Hemophilus influenzae, Glutathione-S-transferase(GST) or beta-galactosidase, relatively large co-proteins whichsolubilize the protein and facilitate production and purificationthereof. Moreover, the co-protein may act as an adjuvant in the sense ofproviding a generalized stimulation of the immune system. The co-proteinmay be attached to either the amino or carboxy terminus of the firstprotein.

Provided by this invention are compositions, particularly vaccinecompositions, and methods comprising the polypeptides or polynucleotidesof the invention and immunostimulatory DNA sequences, such as thosedescribed in Sato, Y. et al. Science 273: 352 (1996).

Also, provided by this invention are methods using the describedpolynucleotide or particular fragments thereof which have been shown toencode non-variable regions of bacterial cell surface proteins in DNAconstructs used in such genetic immunization experiments in animalmodels of infection with Streptococcus pneumoniae will be particularlyuseful for identifying protein epitopes able to provoke a prophylacticor therapeutic immune response. It is believed that this approach willallow for the subsequent preparation of monoclonal antibodies ofparticular value from the requisite organ of the animal successfullyresisting or clearing infection for the development of prophylacticagents or therapeutic treatments of bacterial infection, particularlyStreptococcus pneumoniae infection, in mammals, particularly humans.

The polypeptide may be used as an antigen for vaccination of a host toproduce specific antibodies which protect against invasion of bacteria,for example by blocking adherence of bacteria to damaged tissue.Examples of tissue damage include wounds in skin or connective tissuecaused, e.g., by mechanical, chemical or thermal damage or byimplantation of indwelling devices, or wounds in the mucous membranes,such as the mouth, mammary glands, urethra or vagina.

The invention also includes a vaccine formulation which comprises animmunogenic recombinant protein of the invention together with asuitable carrier. Since the protein may be broken down in the stomach,it is preferably administered parenterally, including, for example,administration that is subcutaneous, intramuscular, intravenous, orintradermal. Formulations suitable for parenteral administration includeaqueous and non-aqueous sterile injection solutions which may containanti-oxidants, buffers, bacteriostats and solutes which render theformulation isotonic with the bodily fluid, preferably the blood, of theindividual; and aqueous and non-aqueous sterile suspensions which mayinclude suspending agents or thickening agents. The formulations may bepresented in unit-dose or multi-dose containers, for example, sealedampules and vials and may be stored in a freeze-dried conditionrequiring only the addition of the sterile liquid carrier immediatelyprior to use. The vaccine formulation may also include adjuvant systemsfor enhancing the immunogenicity of the formulation, such as oil-inwater systems and other systems known in the art. The dosage will dependon the specific activity of the vaccine and can be readily determined byroutine experimentation.

While the invention has been described with reference to certain eraprotein, it is to be understood that this covers fragments of thenaturally occurring protein and similar proteins with additions,deletions or substitutions which do not substantially affect theimmunogenic properties of the recombinant protein.

Compositions, kits and administration

The invention also relates to compositions comprising the polynucleotideor the polypeptides discussed above or their agonists or antagonists.The polypeptides of the invention may be employed in combination with anon-sterile or sterile carrier or carriers for use with cells, tissuesor organisms, such as a pharmaceutical carrier suitable foradministration to a subject. Such compositions comprise, for instance, amedia additive or a therapeutically effective amount of a polypeptide ofthe invention and a pharmaceutically acceptable carrier or excipient.Such carriers may include, but are not limited to, saline, bufferedsaline, dextrose, water, glycerol, ethanol and combinations thereof. Theformulation should suit the mode of administration. The inventionfurther relates to diagnostic and pharmaceutical packs and kitscomprising one or more containers filled with one or more of theingredients of the aforementioned compositions of the invention.

Polypeptides and other compounds of the invention may be employed aloneor in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective,convenient manner including, for instance, administration by topical,oral, anal, vaginal, intravenous, intraperitoneal, intramuscular,subcutaneous, intranasal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered toan individual as an injectable composition, for example as a sterileaqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical applicationfor example in the form of ointments, creams, lotions, eye ointments,eye drops, ear drops, mouthwash, impregnated dressings and sutures andaerosols, and may contain appropriate conventional additives, including,for example, preservatives, solvents to assist drug penetration, andemollients in ointments and creams. Such topical formulations may alsocontain compatible conventional carriers, for example cream or ointmentbases, and ethanol or oleyl alcohol for lotions. Such carriers mayconstitute from about 1% to about 98% by weight of the formulation; moreusually they will constitute up to about 80% by weight of theformulation.

For administration to mammals, and particularly humans, it is expectedthat the daily dosage level of the active agent will be from 0.01 mg/kgto 10 mg/kg, typically around 1 mg/kg. The physician in any event willdetermine the actual dosage which will be most suitable for anindividual and will vary with the age, weight and response of theparticular individual. The above dosages are exemplary of the averagecase. There can, of course, be individual instances where higher orlower dosage ranges are merited, and such are within the scope of thisinvention.

In-dwelling devices include surgical implants, prosthetic devices andcatheters, i.e., devices that are introduced to the body of anindividual and remain in position for an extended time. Such devicesinclude, for example, artificial joints, heart valves, pacemakers,vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinarycatheters, continuous ambulatory peritoneal dialysis (CAPD) catheters.

The composition of the invention may be administered by injection toachieve a systemic effect against relevant bacteria shortly beforeinsertion of an in-dwelling device. Treatment may be continued aftersurgery during the in-body time of the device. In addition, thecomposition could also be used to broaden perioperative cover for anysurgical technique to prevent bacterial wound infections, especiallyStreptococcus pneumoniae wound infections.

Many orthopaedic surgeons consider that humans with prosthetic jointsshould be considered for antibiotic prophylaxis before dental treatmentthat could produce a bacteremia. Late deep infection is a seriouscomplication sometimes leading to loss of the prosthetic joint and isaccompanied by significant morbidity and mortality. It may therefore bepossible to extend the use of the active agent as a replacement forprophylactic antibiotics in this situation.

In addition to the therapy described above, the compositions of thisinvention may be used generally as a wound treatment agent to preventadhesion of bacteria to matrix proteins exposed in wound tissue and forprophylactic use in dental treatment as an alternative to, or inconjunction with, antibiotic prophylaxis.

Alternatively, the composition of the invention may be used to bathe anindwelling device immediately before insertion. The active agent willpreferably be present at a concentration of 1 μg/ml to 10 mg/ml forbathing of wounds or indwelling devices.

A vaccine composition is conveniently in injectable form. Conventionaladjuvants may be employed to enhance the immune response. A suitableunit dose for vaccination is 0.5-5 microgram/kg of antigen, and suchdose is preferably administered 1-3 times and with an interval of 1-3weeks. With the indicated dose range, no adverse toxicological effectswill be observed with the compounds of the invention which wouldpreclude their administration to suitable individuals.

Each reference disclosed herein is incorporated by reference herein inits entirety. Any patent application to which this application claimspriority is also incorporated by reference herein in its entirety.

EXAMPLES

The examples below are carried out using standard techniques, which arewell known and routine to those of skill in the art, except whereotherwise described in detail. The examples are illustrative, but do notlimit the invention.

Example 1 Strain Selection, Library Production and Sequencing

The polynucleotide having the DNA sequence given in SEQ ID NO:1 wasobtained from a library of clones of chromosomal DNA of Streptococcuspneumoniae in E. coli. The sequencing data from two or more clonescontaining overlapping Streptococcus pneumoniae DNAs was used toconstruct the contiguous DNA sequence in SEQ ID NO:1. Libraries may beprepared by routine methods, for example:

Methods 1 and 2 below.

Total cellular DNA is isolated from Streptococcus pneumoniae 0100993according to standard procedures and size-fractionated by either of twomethods.

Method 1

Total cellular DNA is mechanically sheared by passage through a needlein order to size-fractionate according to standard procedures. DNAfragments of up to 11 kbp in size are rendered blunt by treatment withexonuclease and DNA polymerase, and EcoRI linkers added. Fragments areligated into the vector Lambda ZapII that has been cut with EcoRI, thelibrary packaged by standard procedures and E.coli infected with thepackaged library. The library is amplified by standard procedures.

Method 2

Total cellular DNA is partially hydrolyzed with a one or a combinationof restriction enzymes appropriate to generate a series of fragments forcloning into library vectors (e.g., RsaI, PalI, AluI, Bsh1235I), andsuch fragments are size-fractionated according to standard procedures.EcoRI linkers are ligated to the DNA and the fragments then ligated intothe vector Lambda ZapII that have been cut with EcoRI, the librarypackaged by standard procedures, and E.coli infected with the packagedlibrary. The library is amplified by standard procedures.

    __________________________________________________________________________    #             SEQUENCE LISTING                                                   - -  - - (1) GENERAL INFORMATION:                                             - -    (iii) NUMBER OF SEQUENCES: 2                                           - -  - - (2) INFORMATION FOR SEQ ID NO:1:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 900 base - #pairs                                                 (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: double                                                      (D) TOPOLOGY: linear                                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                               - - ATGACTTTTA AATCAGGCTT TGTAGCCATT TTAGGACGTC CCAATGTTGG GA -            #AGTCAACC     60                                                                 - - TTTTTAAATC ACGTTATGGG GCAAAAGATT GCCATCATGA GTGACAAGGC GC -            #AGACAACG    120                                                                 - - CGCAATAAAA TCATGGGAAT TTACACGACT GATAAGGAGC AAATTGTCTT TA -            #TCGACACA    180                                                                 - - CCAGGGATTC ACAAACCTAA AACAGCTCTC GGAGATTTCA TGGTTGAGTC TG -            #CCTACAGT    240                                                                 - - ACCCTTCGCG AAGTGGACAC TGTTCTTTTC ATGGTGCCTG CTGATGAAGC GC -            #GTGGTAAG    300                                                                 - - GGGGACGATA TGATTATCGA GCGTCTCAAG GCTGCCAAGG TTCCTGTGAT TT -            #TGGTGGTG    360                                                                 - - AATAAAATCG ATAAGGTCCA TCCAGACCAG CTCTTGTCTC AGATTGATGA CT -            #TCCGTAAT    420                                                                 - - CAAATGGACT TTAAGGAAAT TGTTCCAATC TCAGCCCTTC AGGGAAATAA CG -            #TGTCTCGT    480                                                                 - - CTAGTGGATA TTTTGAGTGA AAATCTGGAT GAAGGTTTCC AATATTTCCC GT -            #CTGATCAA    540                                                                 - - ATCACAGACC ATCCAGAACG TTTCTTAGTT TCAGAAATGG TTCGCGAGAA AG -            #TCTTGCAC    600                                                                 - - CTAACTCGTG AAGAGATTCC GCATTCTGTA GCAGTAGTTG TTGACTCTAT GA -            #AACGAGAC    660                                                                 - - GAAGAGACAG ACAAGGTTCA CATCCGTGCA ACCATCATGG TCGAGCGCGA TA -            #GCCAAAAA    720                                                                 - - GGGATTATCA TCGGTAAAGG TGGCGCTATG CTTAAGAAAA TCGGTAGCAT GG -            #CCCGTCGT    780                                                                 - - GATATCGAAC TCATGCTAGG AGACAAGGTC TTCCTAGAAA CCTGGGTCAA GG -            #TCAAGAAA    840                                                                 - - AACTGGCGCG ATAAAAAGCT AGATTTGGCT GACTTGGGCT ATAATGAAAG AG -            #AATACTAA    900                                                                 - -  - - (2) INFORMATION FOR SEQ ID NO:2:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 299 amino - #acids                                                (B) TYPE: amino acid                                                          (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                               - - Met Thr Phe Lys Ser Gly Phe Val Ala Ile Le - #u Gly Arg Pro Asn        Val                                                                              1               5  - #                10  - #                15              - - Gly Lys Ser Thr Phe Leu Asn His Val Met Gl - #y Gln Lys Ile Ala Ile                  20      - #            25      - #            30                   - - Met Ser Asp Lys Ala Gln Thr Thr Arg Asn Ly - #s Ile Met Gly Ile Tyr              35          - #        40          - #        45                       - - Thr Thr Asp Lys Glu Gln Ile Val Phe Ile As - #p Thr Pro Gly Ile His          50              - #    55              - #    60                           - - Lys Pro Lys Thr Ala Leu Gly Asp Phe Met Va - #l Glu Ser Ala Tyr Ser      65                  - #70                  - #75                  - #80        - - Thr Leu Arg Glu Val Asp Thr Val Leu Phe Me - #t Val Pro Ala Asp Glu                      85  - #                90  - #                95               - - Ala Arg Gly Lys Gly Asp Asp Met Ile Ile Gl - #u Arg Leu Lys Ala Ala                  100      - #           105      - #           110                  - - Lys Val Pro Val Ile Leu Val Val Asn Lys Il - #e Asp Lys Val His Pro              115          - #       120          - #       125                      - - Asp Gln Leu Leu Ser Gln Ile Asp Asp Phe Ar - #g Asn Gln Met Asp Phe          130              - #   135              - #   140                          - - Lys Glu Ile Val Pro Ile Ser Ala Leu Gln Gl - #y Asn Asn Val Ser Arg      145                 1 - #50                 1 - #55                 1 -      #60                                                                              - - Leu Val Asp Ile Leu Ser Glu Asn Leu Asp Gl - #u Gly Phe Gln Tyr        Phe                                                                                             165  - #               170  - #               175             - - Pro Ser Asp Gln Ile Thr Asp His Pro Glu Ar - #g Phe Leu Val Ser Glu                  180      - #           185      - #           190                  - - Met Val Arg Glu Lys Val Leu His Leu Thr Ar - #g Glu Glu Ile Pro His              195          - #       200          - #       205                      - - Ser Val Ala Val Val Val Asp Ser Met Lys Ar - #g Asp Glu Glu Thr Asp          210              - #   215              - #   220                          - - Lys Val His Ile Arg Ala Thr Ile Met Val Gl - #u Arg Asp Ser Gln Lys      225                 2 - #30                 2 - #35                 2 -      #40                                                                              - - Gly Ile Ile Ile Gly Lys Gly Gly Ala Met Le - #u Lys Lys Ile Gly        Ser                                                                                             245  - #               250  - #               255             - - Met Ala Arg Arg Asp Ile Glu Leu Met Leu Gl - #y Asp Lys Val Phe Leu                  260      - #           265      - #           270                  - - Glu Thr Trp Val Lys Val Lys Lys Asn Trp Ar - #g Asp Lys Lys Leu Asp              275          - #       280          - #       285                      - - Leu Ala Asp Leu Gly Tyr Asn Glu Arg Glu Ty - #r                              290              - #   295                                               __________________________________________________________________________

What is claimed is:
 1. An isolated polynucleotide comprising a firstpolynucleotide or the full complement of the entire length of the firstpolynucleotide, wherein the first polynucleotide encodes a polypeptidecomprising an amino acid sequence as set forth in SEQ ID NO:2.
 2. Avector comprising the isolated polynucleotide of claim
 1. 3. An isolatedhost cell comprising the vector of claim
 2. 4. The isolatedpolynucleotide of claim 1, wherein the isolated polynucleotide comprisesthe first polynucleotide.
 5. A vector comprising the isolatedpolynucleotide of claim
 4. 6. An isolated host cell comprising thevector of claim
 5. 7. A process for producing a polypeptide comprisingculturing the host cell of claim 6 under conditions sufficient forproduction of the polypeptide, which polypeptide is encoded by the firstpolynucleotide.
 8. An isolated polynucleotide comprising a firstpolynucleotide or the full complement of the entire length of the firstpolynucleotide, wherein the first polynucleotide encodes a polypeptideconsisting of an amino acid sequence as set forth in SEQ ID NO:2.
 9. Avector comprising the isolated polynucleotide of claim
 8. 10. Anisolated host cell comprising the vector of claim
 9. 11. The isolatedpolynucleotide of claim 8, wherein the isolated polynucleotide comprisesthe first polynucleotide.
 12. A vector comprising the isolatedpolynucleotide of claim
 11. 13. An isolated host cell comprising thevector of claim
 12. 14. A process for producing a polypeptide comprisingculturing the host cell of claim 13 under conditions sufficient forproduction of the polypeptide, which polypeptide is encoded by the firstpolynucleotide.
 15. An isolated polynucleotide comprising a firstpolynucleotide or the full complement of the entire length of the firstpolynucleotide, wherein the first polynucleotide comprises apolynucleotide sequence as set forth in SEQ ID NO:1.
 16. The isolatedpolynucleotide of claim 15, wherein the isolated polynucleotidecomprises the first polynucleotide.
 17. A vector comprising the isolatedpolynucleotide of claim
 16. 18. An isolated host cell comprising thevector of claim
 7. 19. A process for producing a polypeptide comprisingculturing the host cell of claim 18 under conditions sufficient forproduction of the polypeptide, wherein the polypeptide is encoded by thefirst polynucleotide.
 20. The isolated polynucleotide of claim 15,wherein the isolated polynucleotide comprises the full complement of theentire length of the first polynucleotide.
 21. A vector comprising theisolated polynucleotide of claim
 20. 22. An isolated host cellcomprising the vector of claim
 21. 23. A method for producing antibodiesin a mammal comprising: delivering to a tissue of the mammal a nucleicacid vector to direct expression in vivo of a polypeptide from anisolated polynucleotide of claim 1, wherein the polypeptide is effectiveto induce an immunological response to the polypeptide of SEQ ID NO:2;and, wherein the polypeptide is expressed in vivo and induces animmunological response to produce antibodies to the polypeptide of SEQID NO:2.